Acute myeloid leukaemia: challenges and real world data from India
Open Access
- 9 April 2015
- journal article
- Published by Wiley in British Journal of Haematology
- Vol. 170 (1), 110-117
- https://doi.org/10.1111/bjh.13406
Abstract
The management of acute myeloid leukaemia (AML) in India remains a challenge. In a two‐year prospective study at our centre there were 380 newly diagnosed AML (excluding acute promyelocytic leukaemia, AML‐M3) patients. The median age of newly diagnosed patients was 40 years (range: 1–79; 12·3% were ≤ 15 years, 16·3% were ≥ 60 years old) and there were 244 (64·2%) males. The median duration of symptoms prior to first presentation at our hospital was 4 weeks (range: 1–52). The median distance from home to hospital was 580 km (range: 6–3200 km). 109 (29%) opted for standard of care and were admitted for induction chemotherapy. Of the 271 that did not take treatment the major reason was lack of financial resources in 219 (81%). There were 27 (24·7%) inductions deaths and of these, 12 (44·5%) were due to multidrug‐resistant gram‐negative bacilli and 12 (44·5%) showed evidence of a fungal infection. The overall survival at 1 year was 70·4% ± 10·7%, 55·6% ± 6·8% and 42·4% ± 15·6% in patients aged ≤15 years, 15 ‐ 60 years and ≥60 years, respectively. In conclusion, the biggest constraint is the cost of treatment and the absence of a health security net to treat all patients with this diagnosis.Keywords
Funding Information
- Department of Biotechnology , Ministry of Science and Technology (BT/01/COE/08/03)
- Wellcome Trust (IA/S/11/2500267)
This publication has 27 references indexed in Scilit:
- Invasive fungal diseases during first induction chemotherapy affect complete remission achievement and long-term survival of patients with acute myeloid leukemiaLeukemia Research, 2014
- Clinical Practice Guideline for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer: 2010 Update by the Infectious Diseases Society of AmericaClinical Infectious Diseases, 2011
- Indian health: the path from crisis to progressThe Lancet, 2011
- Multicenter, Phase II Study of Decitabine for the First-Line Treatment of Older Patients With Acute Myeloid LeukemiaJournal of Clinical Oncology, 2010
- Reducing out-of-pocket expenditures to reduce poverty: a disaggregated analysis at rural-urban and state level in IndiaHealth Policy and Planning, 2008
- Revised Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus GroupClinical Infectious Diseases, 2008
- Economic burden of acute myeloid leukemia: a literature reviewCancer Treatment Reviews, 2004
- Costs of Diagnosis, Treatment, and Follow Up of Patients with Acute Myeloid Leukemia in the NetherlandsJournal of Hematotherapy & Stem Cell Research, 2001
- Costs over time in conventional treatment of acute myeloid leukaemia: A study exploring changes in treatment strategies over two decadesJournal of Internal Medicine, 1994
- Proposals for the Classification of the Acute Leukaemias French‐American‐British (FAB) Co‐operative GroupBritish Journal of Haematology, 1976